

AO 120 (Rev. 08/10)

TO: Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	---

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court _____ for the District of Delaware _____ on the following

☐ Trademarks or ☒ Patents. (☐ the patent action involves 35 U.S.C. § 292.):


DOCKET NO.	DATE FILED 8/28/2015	U.S. DISTRICT COURT for the District of Delaware
PLAINTIFF MERCK SHARP & DOHME CORP.		DEFENDANT ROYALTY PHARMA COLLECTION TRUST
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 6,303,661	10/16/2001	Royalty Pharma Collection Trust
2 6,803,357	10/12/2004	Royalty Pharma Collection Trust
3 7,157,429	1/2/2007	Royalty Pharma Collection Trust
4 6,890,898	5/10/2005	Royalty Pharma Collection Trust
5 7,078,381	7/18/2006	Royalty Pharma Collection Trust

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading		
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK	
1			
2			
3			
4			
5			

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT Dismissed - See attached
--

CLERK John A Cerino, Clerk United States District Court 844 N. King Street, Unit 118 Wilmington, DE 19801	(BY) DEPUTY CLERK 	DATE 12/12/16
---	---	------------------

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

AO 120 (Rev. 08/10)

TO: Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450	REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK
---	---

In Compliance with 35 U.S.C. § 290 and/or 15 U.S.C. § 1116 you are hereby advised that a court action has been filed in the U.S. District Court _____ for the District of Delaware _____ on the following
☐ Trademarks or ☒ Patents. (☐ the patent action involves 35 U.S.C. § 292.):


DOCKET NO.	DATE FILED 8/28/2015	U.S. DISTRICT COURT for the District of Delaware
PLAINTIFF MERCK SHARP & DOHME CORP.		DEFENDANT ROYALTY PHARMA COLLECTION TRUST
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 7,459,428	12/2/2008	Royalty Pharma Collection Trust
2 7,829,530	11/9/2010	Royalty Pharma Collection Trust
3 8,318,669	11/27/2012	Royalty Pharma Collection Trust
4 8,513,190	8/20/2013	Royalty Pharma Collection Trust
5 9,044,424	6/2/2015	Royalty Pharma Collection Trust

In the above—entitled case, the following patent(s)/ trademark(s) have been included:

DATE INCLUDED	INCLUDED BY <input type="checkbox"/> Amendment <input type="checkbox"/> Answer <input type="checkbox"/> Cross Bill <input type="checkbox"/> Other Pleading		
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK	
1			
2			
3			
4			
5			

In the above—entitled case, the following decision has been rendered or judgement issued:

DECISION/JUDGEMENT <i>Dismissed - See attached</i>

CLERK John A. Gerino, Clerk United States District Court 844 N. King Street, Unit 18 Wilmington, DE 19801	(BY) DEPUTY CLERK 	DATE 12/16/16
---	---	------------------

Copy 1—Upon initiation of action, mail this copy to Director Copy 3—Upon termination of action, mail this copy to Director
Copy 2—Upon filing document adding patent(s), mail this copy to Director Copy 4—Case file copy

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

MERCK SHARP & DOHME CORP.,
Plaintiff/ Counterclaim Defendant,
v.
ROYALTY PHARMA COLLECTION TRUST,
Defendant/Counterclaim Plaintiff.

C.A. No. 15-757-GMS

JURY TRIAL DEMANDED

STIPULATION AND [PROPOSED] ORDER OF DISMISSAL

IT IS HEREBY STIPULATED AND AGREED, by and among Plaintiff/Counterclaim Defendant Merck Sharp & Dohme, Corp. ("Merck") and Defendant/Counterclaim Plaintiff Royalty Pharma Collection Trust ("Royalty Pharma"), by and through their below attorneys, that:

WHEREAS, on or about August 28, 2015, Merck filed this action against Royalty Pharma, seeking, inter alia, a declaration that certain of the United States Patents owned and or licensed to Royalty Pharma as indicated in the pleadings filed in this Court (the "patents-in-suit")¹ are not infringed or are not valid as they relate to Merck's Sitagliptin Products (including Januvia, Janumet, and Janumet XR)(the "Merck Sitagliptin Products"); and Royalty Pharma denied Merck's claims and counterclaimed in that action for breach of contract under certain License Agreements for Merck's refusal to continue to pay royalties under those License Agreements, and the parties in this Delaware Action have exchanged contentions and disclosed their respective positions on the validity and infringement of the patents-in-suit; and therefore

¹ U.S. Patent No. 6,303,661 ("661 Patent"), U.S. Patent Nos. 6,890,898 ("898 Patent"), 6,803,357 ("357 Patent"), 7,157,429 ("429 Patent"), 7,829,530 ("530 Patent"), 7,078,381 ("381 Patent"), 7,459,428 ("428 Patent"), 8,318,669 ("669 Patent"), 8,513,190 ("190 Patent") and 9,044,424 ("424 Patent") (the "patents-in-suit").

Merck stipulates and irrevocably acknowledges and agrees that the claims of the patents-in-suit are valid and enforceable, remain in full force and effect, and that the Merck Sitagliptin Products are covered by claims of the patents-in-suit; and, further

The Parties Stipulate that, pursuant to Fed. R. Civ. P. 41(a)(1)(A), that all claims asserted by Merck against Royalty Pharma in the above-captioned action shall be hereby dismissed, with prejudice, and all counterclaims asserted by Royalty Pharma against Merck shall be hereby dismissed without prejudice, and further that each side to bear its own costs and attorneys' fees.

McCARTER & ENGLISH, LLP

/s/ Daniel M. Silver

Michael P. Kelly (#2295)
Daniel M. Silver (#4758)
Benjamin A. Smyth (#5528)
Renaissance Centre
405 N. King Street, 8th Floor
Wilmington, Delaware 19801
(302) 984-6300
mkelly@mccarter.com
dsilver@mccarter.com
bsmyth@mccarter.com

*Attorneys for Plaintiff
Merck Sharp & Dohme Corp.*

RICHARDS LAYTON & FINGER, P.A.

/s/ Kelly E. Farnan

Kelly E. Farnan (#4395)
Christine D. Haynes (#4697)
One Rodney Square
920 N. King Street
Wilmington, DE 19801
(302) 651-7700
farnan@rlf.com
haynes@rlf.com

*Attorneys for Defendant
Royalty Pharma Collection Trust*

DATED: December 15, 2016

SO ORDERED this 19th day of Dec, 2016.


United States District Judge